Collegium Pharmaceutical (COLL) Cash & Current Investments (2014 - 2026)
Collegium Pharmaceutical (COLL) posted quarterly Cash & Current Investments of $288.5 million for Q1 2026, up 45.87% year-over-year from $197.8 million in Q1 2025, and up 14.89% quarter-over-quarter from $251.1 million in Q4 2025.
Collegium Pharmaceutical (COLL) Cash & Current Investments (2014 - 2026) Analysis & Trends
Collegium Pharmaceutical's Cash & Current Investments history runs 13 years deep, the most recent figure standing at $288.5 million for Q1 2026.
- In Q1 2026, Cash & Current Investments rose 45.87% year-over-year to $288.5 million; the TTM figure through Mar 2026 stood at $288.5 million (up 45.87% YoY), while the FY2025 annual figure was $251.1 million, up 54.27% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $288.5 million, up from $251.1 million in the prior quarter.
- The five-year high for Cash & Current Investments was $325.5 million in Q2 2023, with the low at $106.7 million in Q1 2022.
- The 5-year median for Cash & Current Investments is $251.1 million (2025), against an average of $222.4 million.
- The sharpest annual moves came in 2023 and 2024: Cash & Current Investments surged 165.21% in 2023, then slumped 60.61% in 2024.
- Collegium Pharmaceutical's Cash & Current Investments stood at $173.7 million in 2022, then surged by 78.8% to $310.5 million in 2023, then sank by 47.59% to $162.8 million in 2024, then soared by 54.27% to $251.1 million in 2025, then gained by 14.89% to $288.5 million in 2026.
- Business Quant data shows COLL's Cash & Current Investments at $288.5 million in Q1 2026, $251.1 million in Q4 2025, and $285.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 963.33 Mn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 5.80 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 2.66 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 389.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 164.00 Mn |
| 10 | Collegium Pharmaceutical | 887.15 Mn | 737.84 Mn | 110.29 Mn | 149.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 149.32 Mn |
| Mar 31, 2026 | 288.50 Mn |
| Dec 31, 2025 | 251.10 Mn |
| Sep 30, 2025 | 285.86 Mn |
| Jun 30, 2025 | 137.20 Mn |
| Mar 31, 2025 | 197.77 Mn |
| Dec 31, 2024 | 162.76 Mn |
| Sep 30, 2024 | 119.96 Mn |
| Jun 30, 2024 | 271.63 Mn |
| Mar 31, 2024 | 318.05 Mn |
| Dec 31, 2023 | 310.55 Mn |
| Sep 30, 2023 | 304.57 Mn |
| Jun 30, 2023 | 325.47 Mn |
| Mar 31, 2023 | 269.48 Mn |
| Dec 31, 2022 | 173.69 Mn |
| Sep 30, 2022 | 134.13 Mn |
| Jun 30, 2022 | 122.72 Mn |
| Mar 31, 2022 | 106.70 Mn |
| Dec 31, 2021 | 186.43 Mn |
| Sep 30, 2021 | 193.24 Mn |